false

  • News & opinion false false
  • News false false
  • 2026 false false
  • CBD ineffective in treating behavioural problems in children with intellectual disability true true

/content/dam/corporate/images/news-and-opinion/news/2026/november/cbd-oil-drops.jpeg

50%

Cannabidiol not effective for treating severe behavioural problems in children with intellectual disabilities

Research finds that CBD oil was not effective at treating severe behavioural problems, such as anxiety, sleep disturbance, irritability, aggression or self-injury.

20 November 2026

m-hero--style-center-wide cmp-teaser--featured m-content-w-image--sandstone

1280.1280.jpeg 1280w, 220.143.2x.jpeg 440w, 800.521.2x.jpeg 1600w, 1440.937.2x.jpeg 2880w, 440.286.2x.jpeg 880w

false

A world-first randomised controlled trial has found that cannabidiol – commonly referred to as CBD – is not effective in treating severe behavioural problems in children with intellectual disability.

Published today in JAMA: Pediatrics, the Australian-led trial found that CBD was not effective in treating severe behavioural problems, such as anxiety, sleep disturbance, irritability, aggression, self-injury or elopement (wandering or running away), in children with intellectual disability aged between 6 and 18 years, as reported by parents using a standardised checklist.

It found that, in this cohort, adverse effects associated with taking CBD are mild and infrequent. Excessive drowsiness, insomnia, diarrhoea and decreased appetite were the most commonly reported.

Cannabidiol is a non-intoxicating compound extracted from the cannabis or hemp plant that does not contain tetrahydrocannabinol, the compound which causes a ‘high’. It has become a popular product worldwide represented by a multi-billion dollar industry. Until now, there have been few studies focused on CBD for severe behavioural problems in children with intellectual disability, and no randomised controlled trials – the gold standard for assessing whether a treatment is effective.

The study was led by Murdoch Children's Research Institute in Melbourne and included researchers from the University of Sydney and Monash University.

Professor of Paediatrics and Child Health at the University of Sydney and Consultant Paediatrician at the Sydney Children’s Hospitals Network, Elizabeth Elliott, recruited, treated and assessed the Sydney cohort. She said: “Many children with intellectual disability experience severe behavioural problems, including irritability, aggression and self-injury. Some parents tell us they spend a significant amount on CBD in an effort to help their children, despite a lack of evidence for its effectiveness. 

“CBD has recently become a popular alternative therapy, given that many medications, including antipsychotics, psychostimulants and antidepressants are common in this group with limited impact and a risk of adverse effects.

“Many parents hoped CBD would be a solution, given its low risk of adverse effects and the perception that it is a more natural option. However, our study showed that CBD is ineffective in treating these behavioural problems in children with intellectual disability.

“Rigorous testing of alternative therapies, such as CBD, is essential, both to avoid creating false hope and to ensure resources are directed towards developing and funding access to effective treatments.”

Professor Katrina Williams from Monash University said: “We wanted to investigate a therapy that might help the many families with a child or young person whose behaviour creates risks and challenges in everyday life. We know existing interventions can be costly, time-consuming or have side effects that many people find difficult to tolerate.

“Despite early promise, cannabidiol is not an effective intervention for these families, children and young people. It is important to establish this, so families can avoid the opportunity costs and financial burden of cannabidiol treatment, and efforts can instead focus on alternative ways to support them.”

While 84 per cent of the 131 participants were diagnosed with autism, the study did not focus on any one particular genetic or developmental condition. Instead, it focused on children with intellectual disability associated with a range of diagnoses and behavioural difficulties.

In the United States, several studies have documented families using CBD to manage behavioural and psychological difficulties in children with autism and other neurodevelopmental conditions, despite limited clinical evidence. In a 2023 survey nearly one-third of parents of children with ADHD, autism and/or anxiety had given their child unlicensed CBD products. Another study of US health records suggests that about one-third of children receiving pharmaceutical CBD may be receiving it without a recorded FDA-approved indication.

How the trial worked

The study was a parallel-design, double-blind, placebo-controlled randomised clinical trial conducted over four years, between 2021 and 2025.

It involved 131 children and adolescents aged between 6 and 18 years, diagnosed with intellectual disability and severe behavioural problems. Participants were recruited from three children's hospitals: the Royal Children's Hospital in Melbourne, Monash Children's Hospital in Melbourne and The Children's Hospital at Westmead in Sydney.

Of the participants, 25.2 per cent were female and 74.8 per cent were male. Participants were randomly assigned to receive either CBD isolate in oil (the purest form available, dosed at 10 mg per kilogram per day) or a placebo orally for eight weeks, followed by a four-week follow-up period. Parents reported scores on the Aberrant Behavior Checklist Irritability (ABC-I) subscale, which were assessed at the end of the eight-week maintenance phase.

Earlier this year, a major University of Sydney-led study found no evidence to suggest medicinal cannabis is effective for depression, anxiety or PTSD in adults. Medicinal cannabis is an umbrella term that refers to both CBD and THC products.

Research

Efron, D. et. al. ‘Cannabidiol for Severe Behavioral Problems in Youths With Intellectual Disability’, JAMA Pediatrics.  
DOI: 10.1001/jamapediatrics.2026.5383

Declaration

The study was supported by the Medical Research Future Fund (grant number: MRF1199507), the National Health and Medical Research Council (grant number: 2026176) and the Victorian government Operational Infrastructure Support Program. Investigational product (both cannabidiol and placebo) was manufactured in kind by Epsilon Healthcare using raw cannabidiol isolate awarded to the trial team through application to the Victorian government.  The trial was approved by the human research ethics committee at The Royal Children’s Hospital. Professor Elliott declares no competing interests. For the full list of competing interest disclosures from other authors, please see the paper. 

Manual Name : Luisa Low

Manual Description : Senior Media Adviser

Manual Address :

Manual Addition Info Title :

Manual Addition Info Content :

Profile image :

Manual Type : contact

alt

_self

Auto Type : contact

Auto Addition Title :

Auto Addition Content :

Auto Name : true

Auto Position : true

Auto Profile image :

Auto Phone Number : false

Auto Mobile Number : true

Auto Email Address : true

Auto Address : false

UUID :